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It has long been known that aging, at both the cellular and organismal levels, contributes to the 
development and progression of the pathology of many chronic diseases.  However, much less 
research has examined the inverse relationship––the contribution of chronic diseases and their 
treatments to the progression of aging-related phenotypes.  Here, we discuss the impact of three 
chronic diseases (cancer, HIV/AIDS, and diabetes) and their treatments on aging, putative 
mechanisms by which these effects are mediated, and the open questions and future research 
directions required to understand the relationships between these diseases and aging. 
 
 




The geroscience hypothesis, that aging is the major modifiable risk factor for most chronic diseases, is 
currently well accepted and it is being tested in multiple models and systems, ranging from basic 
biology in a variety of organisms to preclinical and clinical studies. Aging has been recognized for 
years as a major risk factor for most chronic diseases that affect the aged population. However, it has 
traditionally been overlooked as a non-modifiable risk factor, and thus neglected in most of our 
approaches to medicine. This has changed recently because of the recognition, among basic biology 
of aging researchers, of a limited number of pillars that seem to be the main drivers of the aging 
process. Identification of these pillars was made possible by a multipronged approach based on the 
now classical tenets of aging biology: caloric restriction, cell senescence, and free radicals. While the 
initial theories and concepts driving each of these fields have been subjected to modifications and re-
definitions, research based on these tenets has allowed researchers to identify the major drivers of the 
process. This in turn has led to the beginnings of efforts aimed at translating the findings through the 
use of pharmacological approaches aimed at one or more of the pillars of aging, with the hope that, by 
addressing these fundamental drivers, a positive impact might be achieved in combating not one, but 
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On the other hand, it is well established that aging and disease susceptibility are highly 
variable among individuals within the human population, most likely due to variations in the well-
known interactions between genes and environment. Against this background, a major environmental 
variable known epidemiologically to affect the ―rate of aging‖ (colloquially understood, as there is no 
agreed-upon definition or measure for the rate of aging) is exposure to early serious disease. It has 
been well established, at the epidemiological level, that early exposure to severe diseases and/or their 
treatments leads to an acceleration of aging, as defined by an increased and premature risk of 
developing diseases and conditions that are associated with increased age. In order to narrow the 
discussion, in the Second Geroscience Summit, held on April 13–14, 2016 in New York, New York, 
we focused on three examples: cancer, HIV/AIDS, and diabetes. This was driven simply by the need 
to limit the scope of the discussions, but it is expected that the issues raised will apply, with 
modifications, to all or most diseases that, while curable, nevertheless leave sequelae that are likely to 
affect later increased susceptibility to age-related diseases and conditions. 
That serious disease and/or their treatments lead to an acceleration of disease susceptibility 
later in life is well established at the epidemiological level. The goal of the summit was to dig further 
and try to assess possible molecular and cellular mechanisms that might be responsible for the 
epidemiological observations. A specific emphasis was placed on links between diseases and/or 
treatment and the major pillars of aging, with the assumption that if these early life events affect some 
of the same pillars that have been associated with aging, then this should be a good place to start 
addressing the relationship between the two. 
 
Geroscience as a multidisciplinary approach to understanding aging 
Richard J. Hodes 
 
The extramural program of the National Institute on Aging (NIA) at the National Institutes of Health 
(NIH) is organized around four divisions, and each is poised to make unique and substantive 
contributions to the field of geroscience.  The Division of Aging Biology is the lead for geroscience at 
the NIA, and its focus is on the basic biochemical, genetic, and physiological mechanisms underlying 
the process of aging and age-related changes in humans and in animal models of human aging.  
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dementias of old age, as well as understanding the processes associated with the normally aging brain.  
The basic science research funded by this division intersects with geroscience in the areas of biologic 
mechanisms of disease (e.g., dementias) and age-related changes in the brain that lead to increased 
disease risk.  The Division of Behavioral and Social Research explores aging at the individual and the 
societal level––and research in areas like the biological mediators of social stressors provides a 
connection to geroscience.  Lastly, the NIA’s Division of Geriatrics and Clinical Gerontology 
supports research on health and disease in the aged and research on aging over the human life span; its 
focus on aging-related diseases offers a close link to geroscience. 
Similar connections can be made throughout the NIH.  The NIH comprises 27 different 
institutes and centers (ICs), and nearly all of them investigate at least some diseases and conditions for 
which aging is a risk factor.  Aging-related changes affect bodily functions at every level, from 
cellular metabolism and inflammatory responses to proteostasis and epigenetic modifications.  These 
changes that occur with age have been termed the ―pillars of geroscience‖ (Fig. 1).  It is the 
intersection of these processes with the mechanisms underlying many critical aging-related diseases 
that drives a common interest for NIA and the NIH ICs that support research on these diseases. 
The need to raise awareness of the role of aging biology in disease development prompted the 
NIA––along with 20 other ICs at the NIH––to form a geroscience interest group (GSIG).  The GSIG 
helped to organize an initial Geroscience Summit in 2013, which resulted in several activities, 
including papers, a book, and some multi-institute funding opportunity announcements.  Continued 
NIH and extramural community interest in the field led to the organization of a second summit, 
reported here, in April 2016.  
Over the past several years, a number of science advances illustrate these connections and, 
importantly, the unique role that aging can play in disease development, as well as in responses to 
disease interventions.  One of the most significant NIA-supported findings of this type was the result 
from the Diabetes Prevention Program studies––led by the National Institute of Diabetes and 
Digestive and Kidney Diseases––that showed an especially profound effect of a lifestyle intervention 
in preventing diabetes in individuals over 60, relative to the effect of the same intervention in younger 
participants.
3
 Basic science studies have also demonstrated the potentially life-saving importance of 
preclinical testing of therapies in older animals.  A 2013 study by Bouchlaka et al.
4
 found that one 
systemic cancer immunotherapy strategy was 100% lethal to older mice after 48 h, yet all of the 
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The geroscience pillars will continue to inform this work as more of it moves from the bench 
through translational research applications to clinical trials.  As just one example, it has been reported 
that removal of senescent cells from an aging mouse through an innovative genetic strategy results in 
enhanced structure and function of muscle and other tissue.
5
  These and other recent findings in model 
systems provide a basis for translation into clinical studies––and meetings like the summit are 
designed to catalyze these discoveries. 
 
 
Disease drivers of aging as a topic of geroscience 
Felipe Sierra 
 
Aging is recognized as the major risk factor for most chronic diseases and disabilities. However, there 
is still a widespread perception that aging is immutable, and thus both research and clinical trials often 
focus on curing or preventing specific diseases rather than addressing the core: aging itself. Against 
this background, researchers have made impressive progress in the last few decades in understanding 
the genetics, biology, and physiology of aging, using a veritable zoo of laboratory animals to model 
human aging.
6
 This has made possible the emergence of the field of geroscience, the intersection 
between basic aging biology and disease.
7
 The aims of geroscience are to understand the molecular 
and cellular basis of how aging enables disease and to exploit that knowledge. Indeed, the geroscience 
hypothesis states that, by reducing the rate of aging, it should be possible to delay or slow down the 
appearance and progression of not one, but most age-related chronic ailments, all at once.
8
 This 
includes life-threatening diseases, such as cancer, vascular disease, diabetes, and many others, as well 
as chronic diseases (arthritis, osteoporosis, mild cognitive impairment) and conditions (frailty, loss of 
resilience, fatiguability) that, while not life threatening themselves, nevertheless severely diminish 
quality of life.  
The trans-NIH GeroScience Interest Group (GSIG) was formed with the goal of promoting 
awareness and discussion on these issues. A major activity of the GSIG has been the summits. The 
first Geroscience Summit, in October 2013, focused on exploring the molecular and cellular 
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aging were identified at that time,
9
 and the door was left open for additional pillars not yet identified. 
One such underexplored pillar could be the appearance of early major diseases and their treatment, 
which has been shown in epidemiological studies to lead to premature or accelerated appearance of 
age-specific traits, including chronic morbidity. As a result, a second Geroscience Summit was co-
organized by the GSIG in conjunction with the American Federation for Aging Research, the Genetics 
Society of America, and the New York Academy of Sciences. The meeting was held in April 2016, 
and it was decided to address the question: What are the molecular and cellular mechanisms that 
might explain why some diseases accelerate the aging process, leading to premature appearance of 
age-related diseases and conditions? The fact that there is such an acceleration has been demonstrated 
extensively in the literature, and therefore further discussion of epidemiological data confirming these 
results was discouraged. Rather, as in the first summit, the emphasis was on molecular and cellular 
events occurring as a function of the disease or its treatment that might impinge on the rate of 
functional deterioration that occurs during normal aging. In an effort to narrow the discussions, three 
diseases were chosen: HIV/AIDS, diabetes, and cancer. Both the effects of the diseases themselves 
and the effects of their treatments were discussed by panelists in three separate sessions, as well as a 
roundtable discussion at the end, focused on identifying open research questions that need to be 
addressed to advance our understanding of how these diseases might affect the aging process. 
While the summit focused separately on the three chosen diseases, it is acknowledged that 
people of advanced age are rarely affected by a single chronic disease; rather, they are often afflicted 
by multiple comorbidities and conditions that limit their health. However, during the discussions, the 
focus was primarily on early appearance of the diseases in relatively young people. In those cases, 
cancer, HIV/AIDS, and diabetes are often found to occur alone, and the initial disease is often 
addressed vigorously. This has led to important increases in survival and extended life span in 
affected individuals. However, comorbidities are observed later, as the patients age, and the summit 
addressed the downstream consequences, in terms of decreased health span, the portion of life spent in 
good health.  
 
 
The geroscience hypothesis:  what do we know? 








The progressive deterioration of physiological function over time, aging occurs even in the absence of 
disease, as shown by the steady decline in performance even of the world’s best master athletes as 
they grow older.  However, aging is intimately associated with a wide range of diseases––virtually all 
the fatal diseases of modern life––because it increases vulnerability to, and compromises the ability to 
recover from, diseases.  Whether diseases themselves can accelerate aging is a hypothesis many 
researchers are currently considering. 
It is important to remember that nonfatal maladies of aging, such as increased joint pain, loss 
of vision and hearing, and muscle weakness, should not be neglected, as they have become 
particularly important in recent times.  As successful as the biomedical community has become at 
delaying death, shown by the steady rise of life expectancy for well over a century, it has not been 
successful at delaying aging itself.  Consequently, the number of people needing joint replacement 
due to chronic pain, cataract surgery due to low vision, or assistance in the simple activities of daily 
living has steadily risen as well.  These chronic fatal and nonfatal maladies of later life have now 
become the number one threat to human health globally.   
In the past 2 decades, the aging research community has been successful at discovering 
methods to extend the life of model laboratory animals. These methods include genetic, dietary, and 
pharmaceutical interventions.  This research has revealed key players, such as insulin/IGF and mTOR 
signaling, in complex, interconnected molecular networks that appear to underlie organismal 
longevity.  However, despite these successes, at least three critical questions remain unanswered.   
First, do life-extending interventions extend health or do they simply delay death?  In terms of 
their ultimate translation into human therapies, this is perhaps the most important unanswered 
question.  Recently, assessment of age-related health trajectories has become a major focus of 
laboratory longevity studies. Certainly, extending the unhealthy period of life near its end is not a goal 
worth pursuing.   
Second, will life-extending interventions be effective outside of the laboratory environment?  
Researchers work very hard to protect their experimental animals from infectious diseases, poor diets, 
and unpredictable environmental events.  Will life––and more importantly health––also be extended 
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interventions, such as dietary restriction, appear to compromise resistance to at least some infectious 
diseases,
10,11
 so that is a substantial consideration in the real world.   
Third, of course, is whether the effects of interventions that were observed in short-lived 
laboratory species will translate into similar effects in longer-lived species, such as humans.  It is well 
known that only a fraction of interventions that successfully treat cancer in mice have turned out to be 
therapeutically viable in humans.
12
  So far, not even a fraction of Alzheimer’s disease therapies have 
translated from success in mice to success in humans.
13
    
There is no way to determine whether this will be true for known interventions in mouse 
aging without performing the human trials.  Such trials, involving older people as participants, would 
not need to be excessively lengthy to detect whether health is extended.  Multiple drug candidates 






The complex bidirectional relationships between chronic disease and telomere attrition  
Elissa Epel 
 
Telomeres are a window into one type of aging—replicative senescence, the inability of mitotic cells 
to continue to divide and, thus, for tissue to replenish.  The most common measure of telomere length 
in human studies is the average telomere length in blood, across all immune cells.  Telomere shortness 
is an early risk factor for immune senescence.  When telomeres reach a critical shortness, the cell 
enters either senescence or apoptosis.  The intracellular enzyme telomerase can promote telomere 
lengthening, preventing the age-related shortening that comes with cell division. 
Telomeres predict disease in humans  
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very common pathway to cell senescence in in humans, partly because we are so long lived.  In lower 
species, telomeres may be a much less important pathway to senescence.  For example, rodents both 
start out with very long telomeres and live shorter lives.  In this case, telomere attrition is only 
important in extreme examples (knockouts and in subsequent generations when telomeres become 
very short).   
Telomeres in humans are helpful as a marker— they are easy to measure in population-based 
studies and are predictive of early onset of diseases of aging, as shown by many meta-analyses.  
Telomere length is also an easy-to-get measure that signals that other likely aspects of cell aging may 
be present.  Short telomeres are bidrectionally related to other aspects of aging biology.  For example, 
dysfunctional telomeres impair mitochondria and lead to systemic inflammation.  Telomeres also play 
a direct mechanistic role in aging, as shown by Mendelian randomization studies (e.g., Ref. 14).  
Disease processes may shorten telomeres 
There is now a robust literature showing that telomere shortness precedes the onset of cardiovascular 
disease and diabetes.  Early telomere attrition creates risk for early diseases of aging.  However, once 
one has a chronic disease, many aspects of the disease process can promote accelerated telomere 
attrition.   While there are a myriad of biochemical alterations in each disease, a common triad 
underlying many diseases of aging is oxidative stress, inflammation, and hyperglycemia/insulin 
resistance.  Diabetes offers a clear example of how the disease process further shortens telomeres.
15
   
Once one has diabetes, the impaired β cell function and resulting higher levels of these biochemical 
stressors can further shorten telomeres.  
This is also apparently the case for major psychiatric diseases.  The presence of psychiatric 
disease is associated with shorter telomeres, particularly for major depression and anxiety disorders.  
There are dose–response relationships such that the longer the duration of the depression, the shorter 
the telomere length.
16
  It may also be that the short telomeres also preceded the onset of the condition, 
and longitudinal studies are needed to determine the strength of causal directions.  Given the high 
comorbidity of medical and psychiatric conditions, it is important to take into consideration that the 
common condition of depression may alter aging biology, not just the physical disease condition.  
Disease treatments modulate telomere attrition 
Treatments for diseases may further affect the rate of telomere attrition, either speeding it up or 
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metformin may prevent telomere attrition.
17
  In contrast, highly active antiretroviral therapy in HIV 
appears to accelerate telomere attrition.   Chemotherapy can work through telomere damage of both 
cancerous cells and healthy cells.
18
 
While cell aging predicts disease, once one has disease, there is undoubtedly a clouded and 
complex picture, where both disease processes and aspects of treatment can further affect telomere 
stability and repair, and thus rate of attrition over time.  There is a tremendous amount that could be 
easily learned by incorporating assessments of cellular aging, such as telomere length, into treatment 
studies. 
 
The bidirectional relationship between stress and HIV 
Gretchen N. Neigh 
 
Individuals living with HIV are subject to a high stressor burden.  This burden includes the influence 
of external stressors, such as financial burden and stigma, as well as the burden of the internal 
stressors of viral presence and antiretroviral medication.  Evidence of the burden of these stressors is 
evident in the increased incidence of stress-related disorders among individuals living with HIV, such 
as depression and posttraumatic stress disorder.
19
  Furthermore, comorbidity of affective disorders 
with HIV affects overall longevity, as demonstrated by the report that women living with depression 
and HIV have higher mortality than euthymic women living with HIV.
20
  
 In order to understand how stressors and HIV may interact, it is important to visualize the 
relationship between stress and stressors.  An organism’s response to a stressor is the physiological 
state of stress, and stress is designed to return the organism to homeostasis.  Similar to a rubber band 
being stretched, the relationship between stressors and stress is initially completely predictable and 
reversible.  The force (stressor) is applied, and the stress response of the organism returns the system 
to homeostasis––the relationship is elastic or resilient.  However, if the stressors are too great, the 
elasticity of the system begins to be compromised such that the force applied does not predictably 
generate the same response and the return to homeostasis may be incomplete or require shifts in 
function––the relationship is adaptable.  If stressors are applied to an extreme point for a prolonged 
period of time, or if a genetic or environmental predisposition exists, then the response generated 
becomes maladaptive.  In the case of HIV, it is likely that the combined stressor burden shifts the 
relationship between stressors and the stress response to the point that a resilient response is less 
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 The stress response can be managed at both the psychosocial and biological levels.  
Regardless of whether the origin of the stressor is psychosocial or biological, the initiated processes in 
the organism are virtually identical––that is, the hypothalamic–pituitary–adrenal (HPA) axis that 
facilitates the stress response does not differentiate between types of stressors.  At the psychosocial 
level, interventions that reduce the impact of stressors, such as stigma, loss, or financial strain, can in 
part minimize the impact of HIV on the stress response system by preventing the initiation of a stress 
response. The biological response to stressors is also affected by HIV.  This level of modulation has 
two primary points of intervention or titration: magnitude and duration.  In terms of magnitude, both 
the cumulative burden of psychosocial stressors
21
 and the impact of viral proteins
22
 have been shown 
to alter the stress response.   
 Although the impact of HIV on the stress response is multifaceted, there are also multiple 
points of intervention.  Psychosocial interventions are useful and important in the context of HIV.  
However, it is valuable to note that the stress-response system of individuals living with HIV is 
different than those without the disease, and it may be necessary to consider biological support for the 
HPA axis in order to allow the patient to reap the full benefits of a psychosocial intervention.  In 
addition, it is vital to recognize that, while antiretroviral therapy is effective in reducing viral loads 
and restoring CD4 counts, these drugs are not without impact, and the influence of these compounds 
on P450 and other aspects of the stress response system can render patients more susceptible to the 
impact of stressors.
23
  Finally, given the ubiquitous nature of  stress hormones, targeted end-organ 
interventions for the systems most affected in an individual demonstrating the repercussions of a 
cumulative stressor burden may be the most effective method of intervention for individuals aging 




From wasting to obesity: HIV and its therapy in aging 
Kristine Erlandson  
 
Some of the earliest manifestations of AIDS were the profound wasting observed with uncontrolled 
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cachexia, the wasting was multifactorial and due in part to nutritional deficiencies, increased resting 
energy expenditure, infections, cancers, and high levels of inflammation.  The result was a significant 
loss in both muscle and fat.  With the advent of effective antiretroviral therapy (ART), these weight 
changes could be partially reversed; however, the impact of HIV and ART on muscle and fat were far 
from over.   Men with a history of wasting gained less weight over time and remained an average of 
nearly 10 kg less than men without a history of wasting.
24
 Importantly, this low muscle mass has been 
associated with increased mortality.
25
   Both ART and HIV were found to have toxic effects on the 
muscle, with many of the older nucleoside reverse transcriptase inhibitor (NRTI) therapies later 
implicated in mitochondrial toxicity.
26
  HIV-infected adults also have been shown to have gene 
expression patterns consistent with fibrosis and collagen deposition
27
 and to have greater fatty 
infiltration of the muscle and decreased strength with aging compared with HIV-uninfected controls.
28
  
The early era of ART was quickly complicated by lipodystrophy, a constellation of changes in 
fat distribution, including both lipoatrophy, a loss of subcutaneous fat of the face and extremities, and 
lipohypertrophy, a gain in visceral, truncal, or dorsocervical fat. Older NRTI therapies have been most 
implicated in lipoatrophy, but there is evidence that all ART can contribute to lipohypertrophy. Even 
the newest ART regimens are associated with marked gains in fat, with some studies showing up to a 
30% increase in visceral fat over just the first 2 years of treatment.
29
  The severity of lipodystrophy 
can range from very mild to quite severe and stigmatizing.  Certain ARTs contribute to a variety of 
additional pathologies in fat that can become more pronounced in the setting of lipodystrophy, 
including mitochondrial toxicity and disruption in adipocyte differentiation. Additionally, the lipolysis 
that occurs in lipoatrophy is associated with an accumulation of free fatty acids, which ultimately may 
be deposited in visceral fat, muscle, or the liver.  More recent data suggests that adipose tissue may 
actually serve as a reservoir for HIV virus, allowing for viral replication and further inflammation and 
subsequent adipose tissue dysfunction (reviewed in Ref. 30).   The favorable weight changes among 
AIDS patients initiating ART were initially attributed to a return to health following a period of 
profound weight loss.  Although the majority of HIV-infected adults now start on ART at much 
earlier stages, well before wasting, this weight gain has continued to occur.  Thus, the problem of 
obesity, often overlapping with lipodystrophy, is now quite common. Regardless of the cause, the 
consequence of both obesity and HIV- or ART-attributed body fat changes are additive and result in 
increased insulin resistance, immune activation, and inflammation. 
Changes in body composition resulting from HIV infection and complications of ART mimic 
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visceral and other ectopic fat. Furthermore, the combination of both low muscle mass and increased 
fat content (referred to as sarcopenic obesity) likely has a synergistic effect in HIV.
25
  These body 
composition changes are associated with changes in mitochondrial function and insulin resistance and 
both contribute to and are worsened by chronic inflammation.  While newer ART will eliminate or 
minimize some of the insults seen early in the AIDS crisis, these changes contribute to comorbid 
disease development.  Not unexpectedly, the result is what appears to be an earlier occurrence or 
worsened severity of many diseases of aging.  Indeed, several cohorts have shown an earlier or more 
profound manifestation of many age-associated conditions, such as frailty, falls, fractures, 
cardiovascular disease, diabetes, cancers, and neurocognitive impairment, in HIV-infected adults.   
With the body composition changes that many older, HIV-infected adults have experienced, 
the risk for age-associated diseases is often markedly underestimated.  Prevention and treatment 
strategies for disease progression must target multiple pathways.  Although we may not be able to 
eliminate the damage done with current ART, interventions targeted at muscle and fat have the 




GDF11 and myostatin: new evidence for roles in aging 
Marissa J. Schafer and Nathan K. LeBrasseur 
 
A central endeavor in geroscience research is to identify circulating mediators of biological aging. If 
such factors exist, harnessing or blocking their action may translate to enormous therapeutic potential. 
Until recently, growth differentiation factor 11 (GDF11) was believed to be a promising 
prorejuvenative protein that declines in the bloodstream throughout chronological aging. Therapeutic 
replenishment to youthful levels was demonstrated to restore regenerative capacity in muscle, heart, 
and brain (reviewed in Ref. 31).  
GDF11 is remarkably homologous to myostatin (MSTN, also known as GDF8), differing in 
amino acid sequence within their mature domains by only 11 residues. GDF11 and MSTN also share 
canonical TGF-β posttranslational processing and signaling, through binding to the activin type I or II 
receptors and subsequent activation of SMAD. In contrast to GDF11’s purported progrowth effects, 
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muscle hypertrophy and hyperplasia. Accordingly, MSTN inhibition is a potential strategy to improve 
muscle-wasting conditions, including sarcopenia, cachexia, and frailty (reviewed in Ref. 32). Thus, a 
central question plagues the field: how can GDF11 and MSTN, doppelgängers in structure and 
signaling, exert antithetical functional effects?   
New discoveries have begun to shed light on this issue, which include several studies 
challenging GDF11’s antiaging, progrowth influence (reviewed in Refs. 33 and 34). A critical 
emerging experimental consideration is the requirement of detection methods that are able to resolve 
GDF11 from MSTN. The aptamer-based profiling platform that was employed in the studies 
implicating GDF11 in rejuvenative processes was unable to distinguish between GDF11 and MSTN. 
Similarly, cross-reactive antibody–based methods have been relied upon. The realization that these 
assays were insufficiently discerning has underscored the need for new detection methods (reviewed 
in Ref. 33). The most robust approaches are anticipated to leverage mass spectrometry (MS) for 
quantification of GDF11- and MSTN-based amino sequence differences. Moreover, methods 
integrating both immunoprecipitation and MS will be useful for determining the physiological 
contexts in which various forms of GDF11 and MSTN (latent versus mature) travel and their 
associations with regulatory proteins, such as follistatin, follistatin-like 3, and GDF-associated serum 
proteins (reviewed in Ref. 35). Indeed, these proteins likely play important context-dependent 
inhibitory or chaperone roles. Whether and how these complexes contribute to differing tissue 
targeting or activation of cognate receptors by GDF11 and MSTN, or changes in various states of 
health, aging, and disease, remain to be seen.  
Explorations of circulatory dynamics may illuminate unknown local versus systemic 
activities. MSTN is expressed predominantly in skeletal muscle, and GDF11 is expressed more 
ubiquitously. Temporal considerations also appear to convey important functional differences. 
Mutation and expression patterns suggest that GDF11 is developmentally requisite, particularly for 
axial patterning, while MSTN wields antigrowth effects throughout development and adulthood. 
Furthermore, in humans, limited studies have interrogated associations between circulating GDF11 
and MSTN abundance and clinically important health outcomes (e.g., physical, cardiovascular, or 
cognitive function). Such data will help substantiate the role of these proteins in aging and, ultimately, 
their therapeutic potential. 
The questions that remain are reminiscent of a game of Clue. Which protein is it? In which 
tissue did it originate, and in which tissue is it exerting influence? Through which mechanisms (e.g., 




This article is protected by copyright. All rights reserved. 
15 
 
and MSTN-specific outcomes, and are these functions conserved in rodents and humans? Recent 








The advent of ARTs has held great promise for the treatment of HIV.  These therapies lower viral 
load, preventing development of AIDS and, ultimately, delaying death.  As a result of ART, 
individuals now regularly live decades after infection without developing life-threatening 
complications.  Unfortunately, while treated individuals enjoy extended life spans relative to what 
they might without ART, patients now appear in the clinic with conditions that resemble premature 
aging––including cognitive impairment, cardiovascular disease, diabetes, osteoporosis, and 
lipodystrophy.
36
  The net effect of these various maladies is a reduced quality of life coupled to a 
shortened life span relative to uninfected individuals.  These comorbidities suggest that one or more 
basic processes of aging is activated by either infection with HIV, the ART treatments that keep HIV 
in check, or both.  While differentiating between these possibilities is challenging (HIV
+
 patients do 
not live long without ART, while HIV
–
 people do not normally receive ART), murine and tissue 
culture models of ART treatment now suggest that these therapeutics activate one or more basic 
proaging processes. 
 What basic biological processes might promote aging in response to ART?  Many ART drugs, 
including the nucleotide reverse transcriptase inhibitors (NRTIs), such as zidovudine and stavudine,
37
 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, can interfere with 
normal mitochondrial function, and thus many have non-viral off-target effects.  NRTIs are most 
commonly associated with mitochondrial dysfunction because they can inhibit mitochondrial DNA 
polymerase γ (POLG), resulting in mitochondrial DNA depletion.  Similarly, efavirenz inhibits 
complex I on the mitochondrial electron transport chain, lowering cellular energy (ATP) levels and 
increasing oxidative stress.
38
  Thus, many ART drugs can induce a state of mitochondrial dysfunction 
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How might ART-induced mitochondrial dysfunction drive age-related conditions?  Both 
mitochondrial DNA depletion and inhibition of complex I induce cellular senescence, a state of 
essentially permanent mitotic arrest.
39
  This mitochondrial dysfunction–associated senescence 
(MiDAS) can drive age-related conditions via two mechanisms.  First, the cellular arrest prevents 
senescent progenitor cells from repopulating a tissue.  Second, MiDAS is accompanied by a 
senescence-associated secretory phenotype (SASP) that is distinct from other known inducers of 
cellular senescence.  The MiDAS SASP consists of a mélange of biologically active molecules that 
can have potent effects on local tissues.  For example, the MiDAS SASP inhibits the differentiation of 
adipocytes.  Indeed, POLG mutant mice––which display profound lipoatrophy––accumulate 
senescent cells at a rapid rate.
39
  Lipoatrophy is also a common consequence of ART, and senescent 
cells appear in adipose tissue of patients that receive some NRTIs.
2
  Thus, senescent cells are 
somewhat of a ―smoking gun‖ as an etiological agent for ART-induced lipoatrophy and possibly other 
age-related phenotypes.   
 Are senescent cells truly causal for age-related conditions associated with ART?  Thus far, the 
evidence is largely correlative, with senescent cells appearing at the right places and times in 
conditions like ART-associated lipoatrophy.  Fortunately, recent murine models in which senescent 
cells are selectively eliminated have shown that senescent cells indeed promote features of aging.
40
  
These types of models hold promise both for determining whether senescent cells promote age-related 
conditions associated with ART and as a potential basis for novel therapeutic interventions aimed at 
eliminating senescent cells.   
 
 
DNA methylation age is accelerated before AIDS-related non-Hodgkin lymphoma diagnosis 
Mary E. Sehl 
 
Diffuse large B cell lymphoma is the most common aggressive non-Hodgkin lymphoma in the United 
States, and its major risk factors include advancing age and immunosuppression.  Markers of chronic 
B cell activation are elevated in both normal aging and HIV infection and are associated with risk of 
developing AIDS-related non-Hodgkin lymphoma (AIDS-NHL).
41
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accumulation of immunosenecent cells and altered methylation of polycomb group target (PCGT) 
genes, which are involved in stem cell self-renewal, and whose methylation is aberrant in dysplasia 
and cancer.
42
   Acceleration of age-related methylation patterns involving CpGs from the PCGT 
pathway have been recently demonstrated in the setting of HIV-1 infection.
43
  The goal of our work is 
to characterize epigenetic patterns that are involved in aging, HIV infection, and lymphomagenesis.   
The epigenetic clock, derived from 8000 samples from 82 Illumina DNA methylation and 
array data sets from 51 healthy tissues and cell types, allows one to estimate DNA methylation 
(DNAm) age of tissues, using methylation levels at 353 CpGs from pathways involved in cell 
apoptosis and survival, self-renewal, and tissue development.
44
  DNAm age is highly correlated with 
chronologic age across tissues and species, correlates with cell passage number, is close to zero for 
embryonic stem cells and iPSCs, is highly heritable, and is applicable across species, and age-
acceleration is seen in some cancer tissues.
44
 An online epigenetic age calculator is available for 
calculation of DNAm age based on data measured using the Illumina Infinium platform (450K or 27K 
data) (https://labs.genetics.ucla.edu/horvath/dnadamage/).  
In our study, we utilize peripheral blood mononuclear cells previously collected from 
participants at the Los Angeles site of the Multicenter AIDS Cohort Study (MACS).  We analyze 
global methylation data from men who later developed AIDS-NHL at two time points (1–4 years and 
> 4 years before diagnosis) and compare it to that of HIV-infected controls matched on CD4
+
 T cell 
count and HIV
–
 controls.  We study participants from a broad age range (early 20s to late 50s).  
Lymphoma subtypes in our study include Burkitt’s lymphoma, diffuse large B cell lymphoma, and 
immunoblastic lymphoma.  
Bisulfite sequencing experiments are performed in the UCLA Human Genetics Core 
Sequencing laboratory using the Illumina Infinium 450K platform.  We analyze global methylation 
data from peripheral blood mononuclear cells from MACS study participants and calculate DNAm 
age for each sample using the epigenetic clock.  Preliminary results of our study confirm earlier 
studies showing that DNAm age is strongly correlated with chronologic age and that HIV-infection is 
associated with age acceleration in the epigenetic clock.  Our laboratory is actively examining age-
acceleration differences in samples from individuals who do and do not later develop lymphoma and 
comparing the degree of acceleration from visits closer to lymphoma diagnosis (1–4 years before) 
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Preliminary results confirm that DNAm age is accelerated in peripheral blood mononuclear 
cells in the setting of HIV infection, and suggest that DNAm age acceleration is increased in the years 
before AIDS-NHL diagnosis. We are well poised in our laboratory to further examine the relationship 
between global methylation changes and elevations in chronic inflammatory markers that occur 




Metabolic microvascular dysfunction as a driver of organ aging  
Rosario Scalia and Satoru Eguchi  
 
Leukocyte–endothelium interaction is a physiologic process necessary to avert development of 
infectious disease. In contrast to its beneficial role within the immunologic response and defense 
mechanisms, leukocyte trafficking appears to also be involved in the pathogenesis of organ tissue 
damage in chronic metabolic disorders. Indeed, increased leukocyte trafficking in response to 
hyperglycemia and insulin resistance has been linked with damage to blood vessels and surrounding 
tissue in diabetes, owing to the production of toxic mediators by activated leukocytes.
45–47 
Physiologically, phagocytic leukocytes perform most of their functions in the extravascular 
compartment. To reach this compartment, they must traverse the vascular endothelium. Therefore, 
interaction of circulating leukocytes with the vascular endothelium is a preliminary, essential step in 
the inflammatory response, and this event occurs on the venular side of the microcirculation.
48
 
Leukocyte–endothelium interactions occur in three steps, each mediated by a specific set of cell 
adhesion molecules expressed on the endothelial cell surface: (1) leukocyte rolling (selectin family 
adhesion molecules (P-selectin, E-selectin)); (2) leukocyte adherence (immunoglobulin family 
adhesion molecules ICAM-1 and VCAM-1); and (3) leukocyte extravasation (ICAM-1 and PECAM-
1). Upregulation of cell adhesion molecules occurs in spontaneously hyperglycemic and obese 
mice.
49,50
 Circulating levels of soluble ICAM-1 and VCAM-1 are increased in diabetic and obese 
patients.
51,52 
Elevated ambient glucose causes increased leukocyte rolling and leukocyte adherence in 
cultured endothelial cell monolayers.
53
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diabetic patients are more adhesive to cultured human endothelium than those obtained from normal 
subjects.
54–56 
Taken together, these data strongly indicate that a pathological inflammatory response 
characterized by enhanced endothelial adhesiveness and increased leukocyte–endothelium 
interactions occurs in the microvasculature during metabolic disorders. At the mechanistic level, loss 
of physiologic endothelial nitric oxide (eNO) appears to be correlated with the vascular inflammation 
of metabolic disorders.
57,58 
We and others have demonstrated that loss of basal eNO levels in 
postcapillary venules rapidly induces inflammatory responses in the microcirculation, characterized 




This inflammatory microangiopathy is likely to be a key contributing factor to accelerated 
aging. Indeed, the aging vascular endothelium experiences a progressive loss of release of eNO, 
associated with endothelial dysfunction.
61 
Reduced release of NO in response to endothelium-









 and mesenteric artery
66
 in rats. The 
mechanism responsible for this age-related endothelial dysfunction has not yet been clearly 
elucidated, but it might involve (1) changes in expression/and or coupling of eNOS,
67–69 
(2) increased 
breakdown of eNO due to an augmented production of superoxide anions,
70,71 
or (3) a gradual loss of 
antioxidant capacity that normally provides cellular protection against reactive oxygen species.
72,73 
 
The loss of physiologic eNO with aging appears to also be correlated with vascular inflammation. 
Thus, aging is associated with enhanced expression of adhesion molecules in the rat aorta
74
 and 
increased adhesion of monocytes to the endothelial cell surface in the rabbit aorta.
75
 Remarkably, 
serum-soluble levels of ICAM-1 and other adhesion molecules are also elevated with aging in 
humans.
76
 Endothelial dysfunction and inflammatory phenotypes in the aging vasculature have been 
linked to damage of large conduit vessels. Studies in aging laboratory animals have demonstrated that 
reduced eNOS levels, associated with vascular inflammation, cause apoptosis of coronary endothelial 
cells
77,78 
and accumulation of atherogenic glycosaminoglycans at the arterial wall.
75 
We have reported 
the occurrence of increased leukocyte–endothelium interactions in the aging F1-F344xBN rat.
79 
The 





 and congestive heart failure
83,84
 greatly increases with aging, 
independent of other risk factors. Thus, full understanding of the cellular mechanisms by which 
metabolic disorders cause alteration in microvascular function is likely to shed new light on the 










How does diabetes affect the seven pillars of aging in the kidney? 
Balakuntalam S. Kasinath 
 
Older age is a risk factor for end-stage kidney disease, the most common cause of which is diabetes. 
Conversely, diabetes induces senescence in the kidney independent of age.
85
 Thus, there is a mutually 
reinforcing interaction between diabetes and aging in kidney injury that merits further investigation. Diabetes 
causes glomerulosclerosis, tubulointerstitial fibrosis, and vascular disease, leading to progressive loss of 
kidney waste-clearance function. Aging is also associated with similar histologic lesions in the kidney 
(nephrosclerosis); in addition, ischemic changes and glomerular collapse may be seen. Here, I review the 
scant information that is available on the interaction between diabetes and aging in the context of the pillars of 
aging. In most of the categories below, diabetes and aging have been separately studied; however, their 
interplay has not been explored in depth. 
Diabetes is associated with increased oxidative stress in the kidney that is augmented by aging.
86
 
Aging appears to stimulate mitochondrial generation of reactive oxygen species in the kidney,
87
 whereas this 
may not be the case in diabetes.
88
 Clinical observations show that, in the presence of pre-existing kidney 
disease, diabetes and aging are risk factors for ischemic stress-induced injury to the kidney. How aging and 
diabetes interact in the kidney’s response to the aforementioned stress factors remains to be explored. 
In both diabetes and aging, monocyte infiltration is commonly seen in the kidney. Kidney cell nuclear 
localization of NF-κB, a master regulator of cytokine expression, is increased in aging rodents.
89
 Exuberant 
inflammatory response appears to contribute to the demise of type 2 diabetic mice. The life span of db/db 
mice with type 2 diabetes is about 1 year, significantly less than that of nondiabetic mice; while tumors are the 
main cause of death in nondiabetic mice, we observed that suppurative inflammation is the main cause of 
fatality in db/db diabetic mice.
90
 Thus, diabetes shortens the life span and changes the cause of death in mice. 
Diabetes also appears to change the type of tumors that occur in aging db/db mice.
90
 More work is needed to 
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Both aging and diabetes are associated with endoplasmic reticulum stress in the kidney. Impaired 
autophagy contributes to kidney injury in diabetes.
91
 Impaired renal autophagy also occurs in aging, probably 
due to Sirt1 deficiency.
92
 Whether aging and diabetes together augment autophagy impairment accelerating 
kidney injury requires investigation. Although ER stress inhibits general protein synthesis, synthesis of 
specific proteins, including matrix proteins, appears not to be inhibited, contributing to kidney fibrosis in both 
of these conditions. A new related development is that endogenous hydrogen sulfide regulates protein 
synthesis in the kidney. Hydrogen sulfide content in the kidney is reduced in diabetes; sodium hydrosulfide, a 
source of hydrogen sulfide, ameliorates kidney injury in diabetic rodents.
93
 Hydrogen sulfide inhibits high 
glucose–induced protein synthesis in renal cells in vitro by stimulating AMP-activated protein kinase, which 
leads to inhibition of mTOR.
94
 We have observed that the kidney hydrogen sulfide content is reduced in aging 
mice (unpublished data). Whether administration of hydrogen sulfide ameliorates aging-induced kidney injury 
is unknown. Whereas rapamycin, an inhibitor of mTOR, prolongs life span in nondiabetic mice, it augments 
mortality in db/db diabetic mice;
90
 the mechanistic basis of this differential response requires future 
exploration. Hydrogen sulfide has been reported to mediate dietary restriction–induced protection of the 
kidney against ischemic injury and extension of life span in worms and yeast.
95
 
Infusion of early endothelial outgrowth cells seems to improve senescence, induce autophagy, and 
ameliorate kidney injury in diabetic mice.
96
 Infusion of bone marrow cells from young mice ameliorates 
senescent changes in the kidney in old mice.
97
 Whether stem cells aid in ameliorating kidney damage in aging 
diabetic mice needs to be investigated. 
DNA damage occurs in the kidney in diabetes and aging. Recent reports indicate that epigenetic 
acetylation markers are increased within genes related to inflammation in peripheral blood monocytes from 
diabetic patients with renal and retinal damage.
98
 Epigenetic mechanisms in the aging kidney are not well 
understood. 
In summary, the interaction of diabetes and aging in the kidney may occur by the potentiation of the 
same mechanistic pathways or by recruitment of different pathways that lead to the same phenotype. With 
rising life span and increasing prevalence of diabetes, it is very likely that we will have to contend with 
increasing numbers of older adults with diabetic kidney disease. Meaningful intervention to reduce morbidity 
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Does diabetes accelerate aging of β cells through hyperglycemia (glucose toxicity) and also 
insulin resistance? 
Jeffrey B. Halter 
 
A consistent decline of β cell function and insulin secretion is a hallmark of aging, as demonstrated in 
rodents and humans.
99
  Aging effects include a decline of both pancreatic islet cell proliferation and β 
cell turnover.
100,101
  The decline in islet proliferative capacity with age in normal mice is modest.  
However, this aging effect is much more dramatic when the proliferative response of older animals to 
partial pancreatectomy, streptozotocin, and exendin-4 (a GLP-1 agonist) is compared with the robust 
responses observed in young animals.
101
   Similarly, young mice are able to increase islet mass and β 
cell proliferation in response to high-fat diet, but older mice cannot.
102
 Thus, loss of islet proliferative 
capacity appears to occur early in life in rodents.  Exposure to high concentrations of glucose in vitro 
can lead to apoptosis of β cells, evidence of glucose toxicity.
99
  Islets from older Sprague Dawley rats 
appear to be more sensitive to glucose-induced apoptosis.
100
 
Pancreatic β cell proliferation appears to be dependent on cell cycle regulation.  There is a 
substantial increase in expression of the cell cycle regulator p16 in islet tissue from older mice who 
demonstrate the age-related decline in islet proliferation.  Overexpression of p16 markedly reduces 
islet proliferation in younger mice to a level similar to that observed in older mice, and knockout of 
p16, preventing p16 from increasing with aging, appears to reverse the age-related decline of islet cell 
proliferation in this model.
103
  Furthermore, p16 is one of the proteins produced from the CDKN2a 
locus. Genetic variation at this locus has emerged as a consistent association with type 2 diabetes risk 
from genome-wide scanning studies in humans.   
Findings from humans parallel age-related changes observed in rodents, including diminished 
insulin secretion in vitro and in vivo, diminished proliferative capacity, and increased sensitivity to the 
apoptotic effects of high glucose exposure.
99
   
A conceptual model for the interaction of aging and diabetes is provided in Figure 2. In the setting 
of the age-related impairment of β cell function, there is a maladaptive response to lifestyle-related 
insulin resistance, leading to more impaired insulin secretion and progression to impaired glucose 
tolerance (prediabetes) and type 2 diabetes. Glucose toxicity from chronic exposure to hyperglycemia, 
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function. In this way, hyperglycemia of diabetes may drive further worsening of βcell function and 





How does activation of inflammatory and coagulation pathways in cancer patients affect 
survivorship and functional status? 
Harvey Jay Cohen  
 
There is a strong epidemiologic association between markers of inflammation and activation of the 
coagulation system with functional decline and survival in non-cancer-bearing older adults, which are 
predictive of subsequent decline.
105
  Moreover, cancer also induces activation of these two systems, 
and inflammation has been included as one of the hallmarks of both cancer and aging.
106,107
  Thus, a 
potentially vicious cycle exists in a patient with cancer such that aging might affect the progress of 
cancer development and that cancer might affect the process of aging simultaneously.  Moreover, the 
introduction of cancer treatments might also accelerate the latter process.  Figure 3 indicates possible 
pathways involved and how they might affect survival and function.   
Thus, inflammation may be initiated in cancer patients by the increased numbers of 
neutrophils and their activation, which can produce increased adhesion and release of free radicals; 
simultaneously, predominantly via the NF-κB pathway, there is increased IL-6, VCAM, IL-1β and 
TNF-α produced. Concomitantly, coagulation is activated by tissue factor (TF) release, and the 
procoagulant state produces D-dimers and fibrin crosslinking. Endothelial activation occurs, indicated 
by increased VCAM, adhesion, and reactive oxygen species.  There is direct interplay between these 
two systems, as D-dimers can increase synthesis and release of IL-1β and PAI-1 from macrophages in 
vitro and TF can induce production of NF-κB, IL-6, and VCAM.
108
  Thus, this is essentially one 
interconnected system.  Treatment can likewise activate these pathways, in part via free radical 
generation, especially for chemotherapy and radiation therapy.  The impact of immunotherapy is not 
clear, although checkpoint inhibitors release immune system inhibition with toxic effects on the host 
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(e.g., anthracycline effect on the heart).  Cancer can also result in an increase in p16 and decreased 
telomere length, which may lead to an increase in senescent cells and further release of inflammatory 
factors, as discussed by Campisi.  
The impact of these pathway activations results in organ and vascular damage. For example, 
IL-6 and other inflammatory factors induce the cachexia syndrome; in animal models, fatigue, 
weakness and cognitive decline are produced by injection of inflammatory cytokines; IL-6 produces 
muscle wasting and bone loss in experimental animals; atherosclerosis, another pathway to fatigue 
and weakness, is induced; GFR is reduced, and inflammation suppresses bone marrow function, 
resulting in anemia.   The cumulative effect of such organ damage can produce a chronic multiple 
organ dysfunction syndrome (CMODS), a chronic analogy of what is frequently seen in intensive care 
units in conditions like sepsis, which similarly but acutely activate the inflammatory and coagulation 
systems.
109
   The CMODS might then produce a premature aging or frailty phenotype resulting in 
decreased function and shorter survival.
110
  
Questions still to be answered include (1) whether we can establish further direct 
experimental evidence that cancer-related inflammation/coagulation activation produces organ 
damage, (2) whether there are common mediators across organ systems or unique ones for each, and 
(3) whether these pathways are targetable to improve function and survivorship as people age.   
 
 
Which animal and/or cellular models are best for studying the effects of cancer and cancer 
therapy on the aging process? 
Judith Campisi 
 
A relatively underappreciated effect of many malignant tumors is their ability to cause genomic 
damage or damage responses in distal tissues.
111
  More generally, paraneoplastic syndromes––
symptoms that are due to cancer but not to the local presence of cancer cells––have been known for 
decades.
112
  In both cases, the ability of tumors to affect distal tissues is thought to derive from 
circulating tumor-derived cytokines, hormones, and other factors.  Notably, the indirect effects of 
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symptoms––partially overlap with phenotypes and pathologies that are common among non-diseased 
elderly.  Thus, cancer, a major age-related disease itself, can also drive the development of noncancer 
pathologies associated with aging.   
 Related to drivers of aging phenotypes and pathologies are many of the cytotoxic and 
genotoxic therapies that are commonly used to treat cancer.  Recent studies show that children who 
were successfully treated for leukemia or lymphoma and are now middle-aged adults suffer from a 
host of age-related diseases that are characteristic of much older individuals.
113
 
 Many anticancer therapies are potent inducers of cellular senescence, a tumor-suppressive 
stress response that entails an irreversible arrest of cell proliferation and development of a complex 
SASP that includes a host of inflammatory cytokines, chemokines, growth factors, and proteases.
114
 
Senescent cells accumulate with age in many mammalian tissues, and many anticancer therapies 
result in a long-term burden of senescent cells.  The persistent presence of senescent cells, and 




 Recently, transgenic mouse models have been developed in which it is possible to selectively 
eliminate senescent cells.  These models show that senescent cells are responsible for a number of 
adverse phenotypes caused by anticancer therapies.  These adverse phenotypes include the 
development of cancer metastases, cardiotoxicity (which often limits the use of these therapies), loss 
of hemostasis, and loss of robust physical activity––phenotypes and pathologies that also increase 
during aging.   
 Many questions remain unanswered regarding how cancer and its treatments can drive aging.  
For example, both tumors and the senescent cells induced by cytotoxic/genotoxic therapies secrete 
many molecules that are proinflammatory immune activators.  Very little is known about which of 
these secreted factors are most important for activating the immune system, which immune 
components are most important for the proaging responses, and whether the secreted factors can drive 
aging phenotypes independent of the immune system.  Likewise, little is known about which distal 
tissues are most affected by tumors, which tissues accumulate the most senescent cells after anticancer 
therapies, and which tissues are most important for the resulting aging phenotypes and pathologies.   
 What types of interventions might be developed to alleviate the effects of tumors and 
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identified as significant drivers, is should be possible to develop therapies to neutralize them or their 
targets.  However, given the complexity of the secretomes of tumors and the SASP,
114
 the proaging 
effects might be caused by multiple factors, thus diminishing the efficacy of single-agent 
interventions.  As the regulatory pathways that activate and maintain tumor secretomes and the SASP 
are identified, strategies can be developed to prevent the development of this phenotype by 
specifically targeting these pathways.  For example, much of the SASP is controlled by p38MAPK 
and NF-κB,
116
 for which inhibitory drugs have already been developed.  A disadvantage of this 
approach is that it requires the continuous presence of the inhibitory drugs, increasing the risk of 
adverse side effects.  A third strategy is to develop drugs that can selectively eliminate senescent cells, 
similar to the effects of the transgene in the mouse models.  At least one such drug (ABT-263) was 
recently identified,
117
 although additional effort will be need to optimize this drug and/or develop 




Functional decline in the older cancer patient: can lifestyle interventions turn back the hands of 
time? And if so, through what mechanism? 
Wendy Demark-Wahnefried 
 
The number of cancer survivors in this country is expanding rapidly, given converging trends toward 
aging and improvements in early detection and treatment.  In 2014, there were roughly 14.5 million 
survivors in the United States, and projections indicate that this number will approach 19 million by 
2024.
118
  This patient population provides an optimal model to study aging, not only because of rising 
numbers of survivors and the fact that most (61%) are age 65 and older,
118
 but more importantly 
because decades of research evidence shows that the process of aging appears to speed up once the 
cancer diagnosis is rendered.   
An example of accelerated aging is provided by longitudinal research on body composition 
that measures change in lean and fat mass after diagnosis (Fig. 4).
119
  Studies initiated in the 1990s 
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and concurrent losses in muscle in the year following diagnosis.  The changes in body composition 
that these patients undergo in 1 year are comparable to 10 years of normal aging.  These results have 
been replicated time and again among breast cancer patients, as well as those with other forms of 
cancer.
120
  The increase in fat mass most likely contributes to a hyperinflammatory state among these 
survivors, and the decrease in muscle mass may be an underlying cause of the accelerated decline in 
physical functioning experienced by these cancer survivors––declines that affect the ability to work, 
perform activities of daily living, and live independently.
121
  Moreover, it is hypothesized that the 
decreases in body protein detected by fairly imprecise methods, such as dual X-ray absorptiometry, 
are also likely to manifest in changes in levels of circulating binding proteins, hormones, and other 
key constituents that are involved in aging, such as DNA repair, immune response, and mitochondrial 
integrity.  Cancer and its many forms of treatment are also likely to influence the microbiome, as well 
as to induce a broad landscape of epigenetic changes that regulate aging.   
While previous studies show that some individuals are either resistant and do not succumb to 
these common cancer- or treatment-induced adverse effects or are resilient and able to bounce back 
from such adversity,  the predictors that portend future health span are currently unknown.  Therefore, 
an opportunity to gain insights into the mechanisms of aging exists through the longitudinal study of 
these populations.    
Another research opportunity that may inform aging research lies in studying the response of 
cancer survivors to interventions.   A healthy lifestyle may be important in restoring body 
composition and functioning to baseline levels.  A handful of studies promoting physical activity and 
a healthful diet and body weight have been conducted to determine if the trajectory of functional 
decline among cancer survivors can be hindered or reversed.  To date, the largest study was the 
Reach-out to ENhancE Wellness (RENEW) in Older Cancer Survivors trial, a two-arm randomized 
controlled trial among 641 older (age 65+) overweight or obese survivors of breast, prostate, or 
colorectal cancer in the United States, Canada, and the United Kingdom.
122
  The intervention, which 
promoted a slow rate of weight loss, a plant-based diet, and resistance and endurance exercise via 
telephone counseling and tailored, mailed print materials, effectively slowed declines in physical 
functioning compared to waitlisted controls.  Secondary analyses showed that survivors who were 
most likely to benefit from the intervention were those with fewer comorbidities who either were not 
as obese at baseline or lost greater amounts of weight over the study period.  Other lifestyle 
interventions in this patient population also show improvements in physical function or performance 
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protein) and energy metabolism (e.g., insulin, c-peptide), with preliminary data gathering on 
telomerase.  Therefore, studying the response to lifestyle interventions, as well as interventions that 
may be more intensive in this patient population, may also provide insights not only into the 
molecular and cellular mechanisms that cause accelerated aging, but to solutions that may potentially 
turn back the hands of time.             




How does cancer treatment affect cognitive aging? 
Tim A. Ahles 
 
Cancer treatments, including chemotherapy and radiation, endocrine, and immune therapies, can 
cause long-term alterations in cognitive function among a subgroup of vulnerable patients.  Risk 
factors for posttreatment decline are similar to factors that influence normal cognitive aging, including 
age, cognitive reserve, genetic factors (apolipoprotein E, catechol-O-methyltransferase, and brain-
derived neurotrophic factor), comorbid conditions, and frailty.
123
  Cancer treatments can have effects 
on specific brain structure and function.  However, cancer treatments also affect multiple systems 
associated with the biology of aging, including causing (1) DNA damage, (2) chronic inflammation, 
(3) cell senescence, (4) oxidative stress,  (5) depletion of stem cell reserve, and (6) shortening of 
telomeres.
123
  Recent research has demonstrated activation of pathways associated with aging, such as 
increased expression of p16INKa and ARF in breast cancer patients treated with chemotherapy
124
 and 
activation of ERK and AKT signaling pathways in a rat model of chemotherapy-induced cognitive 
change.
125
  Further, cancer treatment affects brain structure and function associated with the aging 




 Taken together, the above findings suggest that cancer treatments interact with and may 
accelerate cognitive aging through affecting a broad array of biological systems associated with aging.  
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utilization of broad-based systems theories of aging.  Network/engineering/redundancy theories of 
aging posit that complex biological systems have evolved highly redundant systems that create 
resiliency through tolerance to local system failure.
126
  However, redundancy also leads to damage 
accumulation, particularly if repair mechanisms are not optimal.  Since the brain has limited capacity 
for repair, damage accumulation is particularly problematic.  Therefore, multiple patterns of failure 
can lead to increased vulnerability to cognitive aging through effecting specific systems and/or 
increasing random error/failure.  Sophisticated mathematical models based on graph theory are being 
developed that simulate activity within complex biological systems, including the brain.
126
  An 
advantage of these models is that patterns of failure rate can be simulated to examine the impact on 
the system, thereby generating hypotheses that can be tested in human and animal studies.  
Consequently, mathematical models of complex systems may be an important future addition to 
translational research efforts examining the interface of cognitive aging and cancer treatments. 
The network biology approach described above suggests the need to evaluate resiliency 
across multiple biological systems. Allostatic load refers to cumulative physiological dysregulation 
related to a lifetime of adapting to exposure to physiological and psychological demands.
127
 
Accumulation of allostatic load occurs when adaptive responses to challenges chronically fall outside 
the normal operating range, resulting in wear and tear on the multiple components of the regulatory 
system. Consistent with network theories, these physiological and psychological challenges can 
increase failure accumulation across biological systems, resulting in decreased resiliency. 
Measurement of allostatic load is operationalized as the assessment of biological parameters related to 
risk of disease across several biological systems, including the HPA axis, sympathetic nervous 
system, immune system, cardiovascular system, and metabolic processes. To date, numerous studies 
have demonstrated that high levels of allostatic load are associated with risk of mortality, 
development of specific diseases and frailty, and cognitive decline associated with aging. Allostatic 
load captures the combined effect of multiple biological systems that have individually been found to 
predict age-related cognitive decline.
127
 
 Unanswered questions for future research include (1) which models that describe the 
resiliency and failure of complex systems are most appropriate for guiding research related to 
interactions of aging processes, cancer, and cancer treatments in determining cognitive aging? (2) 
what panel of biomarkers across biological systems best captures system resiliency and vulnerability? 
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Which mechanisms do or do not drive aging in diabetics?  
Nir Barzilai 
 
Diabetes is considered a model for accelerated aging. It is imperative, though, to seek the pathology 
that commonly exists in the elderly and then determine if it is accelerated with diabetes. For example, 
although macrovascular diseases are common in the elderly, recent study suggests that CVD mortality 
and all mortality are not accelerated; in fact, they are decelerated in elderly over the age of 75 who 
have diabetes.
128
 Severe microvascular complications of diabetes––proliferative retinopathy, 
peripheral and autonomic neuropathy, and end stage  (Kimelstein-Wilson kidney) nephropathy––do 
not appear in the non-diabetic elderly and have been demonstrated to be mainly the consequence of 
hyperglycemia rather than aging. Insulin resistance is hallmark of aging and type 2 diabetes mellitus 
(T2DM). Yet insulin resistance is also a stress response and is part of adaptive/protective response to 
deal with extra nutrients. In fact, in animal models there is no centrality to insulin sensitivity in 
predicting life span.
129
 There are numerous models of insulin resistance models that live significantly 
longer; treatment with rapamycin is an example. There are also numerous models with enhanced 
insulin sensitivity with normal or shorter life span; protein tyrosine phosphatase, non-receptor type 1 
(Ptpn1) knockout mice is an example of an insulin-sensitive model with a significantly decreased life 
span.  
The progress in aging has been accelerated by studying models that have extended health and 





 may extend health span and life span in animals. In human studies, in 
addition to prevention of T2DM, metformin also prevents cardiovascular diseases
132
 and is associated 
with less cancer
133
 in T2DM. Furthermore, elderly individuals over 70 years of age with T2DM 
treated with metformin have significantly less mortality than non-diabetic subjects with less diseases 
and obesity.
134




This article is protected by copyright. All rights reserved. 
31 
 
cardiovascular end points in prediabetic subjects.
135
 Metformin has multiple aging-relevant actions at 
the cellular and organismal levels, including activation of AMP-activated kinase (AMPK), decreased 
insulin levels, decreased insulin/insulin-like growth factor-1 (IGF-1) signaling, inhibition of mTOR, 
inhibition of mitochondrial complex I in the electron transport chain, and reduction of endogenous 
production of reactive oxygen species (ROS), but whether it is a superdrug  or whether one or more 
mechanism retards aging is unclear.  Similarly, while acarbose, an α-glucosidase inhibitor, is largely 
unabsorbed in the intestine and slows the absorption of glucose; its antidiabetic mechanism is 
probably not the same mechanism responsible for longevity because correcting glucose by other 
treatments is not associated with similar outcomes. Therefore, understanding drug mechanisms of 
action provides insight for both elderly and diabetic patients to increase translation and intervention 
for the development of the next generation of treatments.  
Metabolism is also controlled by hypothalamic neuron circuits that affect peripheral 
metabolism. Insulin, leptin, and nutrients administered next to or into the hypothalamus can modulate 
insulin action in the periphery. Some of those circuits fail in aging; however, administration of IGF-1 
seems to restore them. Indeed, insulin or IGF-1 actions in the brain are extended to other organs and 
are associated with Alzheimer’s disease (AD),
136
 which may have significance for treatment of 




Understanding and mitigating premature aging due to cancer and chemotherapy 
Arti Hurria 
 
The hallmarks of aging can be utilized as a framework with which to understand the impact of cancer 
therapies on the aging trajectory. The primary mechanisms of action of several cancer treatments 
affect specific hallmarks of aging, such as genomic instability, cellular senescence, and stem cell 
exhaustion.
137
 Furthermore, the primary impact of cancer itself on the patient can accelerate the aging 
process. Hence, cancer and cancer therapy places patients at risk for a premature aging syndrome, 
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Receipt of chemotherapy is a physiologic stressor, which unmasks an individual’s physiologic 
reserve. Some patients are able to tolerate treatment without undue side effects, while others 
experience major side effects that limit the ability to deliver treatment.   Cancer and cancer treatment 
can create symptoms consistent with the frailty phenotype described by Fried and colleagues, 
including slowness, weakness, weight loss, low activity, and fatigue.  When a patient completes the 
chemotherapy course (if no further treatment is required), the patient will recover; however, this rate 
of recovery is variable. Hence, the receipt of treatment can be considered a human model of 
accelerated aging brought on by a physiologic stressor, and, when the stressor is withdrawn, there is 
opportunity to study the individuals’ resilience (i.e., their ability to bounce back to their prior level of 
functioning). 
Although patients recover upon completion of chemotherapy, there is concern in the cancer 
literature that we have placed patients on an accelerated aging trajectory. This hypothesis is supported 
by data collected from cancer survivors who report poorer physical function,
138–140 
poorer quality of 
life,
141,142 
and increased number of comorbidities,
143,144 
as well as risk for cognitive decline.
145,146 
The 







 and increase resting energy expenditure.
154,155 
 
There are several unanswered questions. How does cancer treatment affect the aging 
trajectory? Are patients who receive cancer treatment on a different trajectory of aging that parallels 
normal aging (the phase-shift hypothesis) or are they now on an accelerated aging trajectory where 
functional decline is accelerated in comparison to normal aging (the accelerated-aging hypothesis). 
Are these changes reversible and, if so, what interventions are needed in order to reset to a normal 
aging trajectory? How does aging affect cancer biology and progression? How can cancer and cancer 
therapy be used to further our understanding of the molecular pillars of aging? All of these questions 
are important research directions that can not only inform the risks and benefits of cancer therapy, but 
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Peter W. Hunt 
 
 
Common features of aging in both animal models and humans––including models of accentuated 
aging, like HIV infection––include breakdown in gut barrier function and dysbiosis of the gut 
microbiome. Indeed, in the very earliest stages of HIV infection, gut epithelial barrier function is 
impaired by breakdown of tight junctions between epithelial cells, increased epithelial cell apoptosis, 
and loss of mucosal immunity.  These defects allow for translocation of microbial products into the 
systemic circulation and a chronic inflammatory state.
156
  Markers of gut epithelial barrier dysfunction 
in HIV strongly predict increased mortality, even after suppression of viral replication is achieved 
with antiretroviral therapy,
157
 suggesting that these defects might plausibly play a role in driving 
disease.  Similarly, gut barrier defects are commonly observed with aging in several different species, 
from Drosophila to baboons and humans.
158–160
 While the specific mechanistic pathways that drive 
these gut barrier defects may differ between species and model system, the resultant systemic 
inflammatory state from microbial translocation may well contribute to several end-organ 
complications and an accentuated aging phenotype.  Dysbiosis of the gut microbiome also occurs in 
both HIV infection and aging and may contribute to systemic pathology, not simply through increased 
microbial translocation, but also via the pathologic metabolic products that they produce.  Some of 
these products, such as those of the kynurenine pathway of tryptophan catabolism, may have a 
multitude of deleterious effects on the immune system, the nervous system, and even mental 
health.
161,162
  These mechanistic similarities between HIV and aging provide multiple potential 
therapeutic targets to improve the health span in each setting.  That said, the degree to which dysbiosis 
and microbial translocation are causes or consequences of the inflammatory state in both HIV 
infection and aging remains unclear.  While animal model data suggest a potential causal role of 
dysbiosis and microbial translocation in contributing to multimorbidity and mortality,
158
 targeted 
clinical trials are needed in humans to prove causality in both the HIV and aging fields.  It also needs 
to be recognized that, just as the specific underlying mechanisms leading to dysbiosis and microbial 
translocation in HIV and aging may differ, the optimal strategies for therapeutic interventions may 
also differ.  Nevertheless, recognizing the mechanistic similarities between HIV and aging may help 
prioritize interventional targets to pursue and accelerate our understanding of each condition as these 
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Conclusions and recommendations 
The Second Geroscience Summit, exploring disease drivers of aging, brought together a broad range 
of scientists to discuss issues relevant to basic biology of aging, translation and clinical practice. In 
addition to the scientific presentations, briefly described in the text, many additional participants 
contributed vigorously to the discussions.  
Perhaps the most relevant conclusion from the discussions is that geroscience is probably the 
best platform to address the complex interactions between aging and chronic diseases, not solely as 
stated in the original concept (aging is the major risk factor for diseases), but also as a two-way street, 
where diseases also accelerate the pace of aging. Equally important is the growing realization that 
health is more than the absence of disease, and, thus, when an individual is affected by a major 
disease, the work of the health provider is not done, since even if the disease is eradicated, full health 
is often not yet fully restored. In this context, the possibility of using ―anti-aging‖ approaches as co-
adjuvants in disease fighting emerges as an exciting and promising alternative. Of course, much work 
remains to be done in order to arrive at that end, including the identification of biomarkers for the 
different pillars of aging and further characterization of the individual pillars most directly affected by 
the disease and/or the treatment. In that context, it is useful to remember that, while the pillars of 
aging are often discussed as independent entities, it is well accepted that changes in any of them often 
affect the other pillars. In that manner, it is possible to conclude that a given disease/treatment pair 
affects all the pillars of aging, which complicates future studies and decisions concerning possible 
therapeutic approaches. Thus, it is crucial to carefully dissect which pillars of aging are affected 
directly, earlier, and/or the most. In addition, every individual is likely to be affected in a different 
manner, and thus individualized medicine will be necessary. 
As discussed at the summit, it has become clear that the physiological impact of diseases or their 
treatments can indeed accelerate the phenotypes of normal aging. Among those phenotypes, it is 
important to consider an increased susceptibility to additional major chronic diseases. Another area of 
research uncovered during the discussions pertains to the need to consider early exposure to disease as 
a possible confounder in studies focused on interventions that may reduce the rate of aging, again 
pointing to the need to consider individual differences in likely susceptibilities and needs.   
Finally, the close relationship between the basic biology of aging and the basic biology of 
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interested in different diseases might collaborate with researchers interested in aging to the enhanced 
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Figure 2. Model for age-related hyperglycemia.  Reprinted from Ref. 104. 
 
Figure 3. Inflammation/coagulation in cancer and aging. 
 
Figure 4. Kilogram change in fat (dashed line) and lean (solid line) body mass among 36 breast 
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